Background
The Recipient Epidemiology and Donor Evaluation StudyâIVâPediatric (REDSâIVâP) is a new iteration of prior National Heart, Lung, and Blood Institute (NHLBI) REDS programs that focus on improving transfusion recipient outcomes across the lifespan as well as the safety and availability of the blood supply.
Study Design and Methods
The US program includes blood centers and hospitals (22 including 6 freeâstanding Children's hospitals) in four geographic regions. The Brazilian program has 5 participating hemocenters. A Center for Transfusion Laboratory Studies (CTLS) and a Data Coordinating Center (DCC) support synergistic studies and activities over the 7âyear REDSâIVâP program.
Results
The US is building a centralized, veinâtoâvein (V2V) database, linking information collected from blood donors, their donations, the resulting manufactured components, and data extracts from hospital electronic medical records of transfused and nonâtransfused patients. Simultaneously, the Brazilian program is building a donor, donation, and component database. The databases will serve as the backbone for retrospective and prospective observational studies in transfusion epidemiology, transfusion recipient outcomes, blood component quality, and emerging blood safety issues. Special focus will be on preterm infants, patients with sickle cell disease, thalassemia or cancer, and the effect of donor biologic variability and component manufacturing on recipient outcomes. A rapid response capability to emerging safety threats has resulted in timely studies related to Severe Acute Respiratory Syndrome Corona Virusâ2 (SARSâCoVâ2).
Conclusions
The REDSâIVâP program endeavors to improve donorârecipientâlinked research with a focus on children and special populations while also maintaining the flexibility to address emerging blood safety issues.